Background: Primary aldosteronism (PA) has a reported prevalence of up to 20% in cases of resistant hypertension, but is substantially under-diagnosed due to the lack of specific symptoms and signs. Ambulatory blood pressure (AMBP) monitoring provides a non-invasive method for evaluating circadian BP variations, offers valuable prognostic information and may help to identify PA in patients referred with non-specific hypertension for investigation. Aims: To compare AMBP parameters in hypertensive patients with established PA and those without, and correlate these parameters with cardiovascular outcomes. Methods: AMBP readings were evaluated retrospectively in 407 patients assessed at Monash Heart. Patient demographics, screening aldosterone and renin concentrations, as well as medications were retrieved from medical records. We identified 396 non-PA and 11 PA patients and their cardiovascular events (myocardial infarction, left ventricular hypertrophy, coronary artery disease, atrial fibrillation) were recorded. Statistical significance was set at P < 0.05. Results: Compared to hypertensive patients without established PA, PA patients were younger (mean: 51.5±13.3 vs. 62.2±14.2 years), had higher BP readings (mean: 150/86±20.5/7.4 vs. 134/75±17.2/10.7 mmHg) with similar patterns observed for average daytime and night-time BP. BP load (% daytime and night-time SBP/DBP readings over 135/85 and 120/70 mmHg, respectively) was significantly higher for both systolic and diastolic in PA (mean: 72.4±26.4 and 50.2±25.6 %) compared with the non-PA group (mean: 49.3±28.5 and 21.6±22.7 %). We found that 81% of patients with PA (9/11) had loss of physiological nocturnal BP dipping compared with 44% of the non-PA group (175/396). Rates of cardiovascular events were similar in both groups but may have been confounded by the retrospective nature of this study and lack of long-term follow-up. Conclusion: Our study found that PA was associated with a significant increase in BP load and loss of nocturnal BP dipping which are known risk factors for adverse cardiovascular events. A prospective study is needed to better define AMBP parameters in PA and evaluate their ability to flag underlying PA amongst hypertensive patients. Background: Large artery stiffness, often measured by carotid-femoral pulse wave velocity (cfPWV) is a cardiovascular risk factor, but threshold values are made difficult due to the dependency on the distending blood pressure (BP). Aims: To measure BP dependency of cfPWV in individuals in a clinically approachable manner as a method of addressing the interaction between BP and arterial stiffness. Methods: Brachial BP (oscillometric monitor) and cfPWV (simultaneous carotid tonometry and femoral cuff) were measured in the seated and supine position. The postural change can invoke a change in systemic BP, but will always cause a significant change in hydrostatic pressure across the carotidfemoral path-length. The hydrostatic effect was calculated using vascular path-length estimated from body surface measurements. Change in cfPWV from seated to supine was divided by the combined change in systemic diastolic BP and hydrostatic pressure (∆PWV/∆DP), the BP dependency of cfPWV.
Background: The aim of the Global SYMPLICITY Registry (GSR) is to collect real-world data on the safety and efficacy of renal denervation (RDN) using either the original Symplicity Flex TM renal denervation catheter or the newer-generation Symplicity Spyral TM catheter. Furthermore, a sub-cohort of patients are receiving treatment of renal artery branch vessels in addition to the main renal artery. Aims: To determine safety and efficacy of the Simplicity renal denervation system. Methods: The GSR is a prospective, multi-centre, non-randomized international registry of RDN enrolling up to 3000 patients with uncontrolled hypertension. Patients are followed at 3, 6, 12, 24 and 36 months. Follow-up data collected per routine care includes: clinical assessment, office blood pressure measurement, 24-hour ambulatory blood pressure measurement, blood tests, ECGs, renal artery imaging, and EQ-5D quality of life questionnaire. At the time of the HBPRCA 2017 meeting, six month safety and efficacy data will be available for ~2500 patients and 3-year data will be available on ~1750 patients. Moreover, data from post-hoc analysis of ~270 patients treated with the Symplicity Spyral catheter as well as data on ~90 patients who had RDN treatment in both the main renal artery and branches will be available for presentation. Results and Conclusions: The Global SYMPLICITY Registry is the largest real world database of renal denervation therapy and has enrolled over 2500 patients to date.Thus far, no long-term safety concerns following the renal denervation procedure have been observed with the Symplicity Flex ™ or Spyral ™ systems. Renal denervation in this large real world population resulted in significant reductions in both office and ambulatory blood pressure that were sustained out to 3 years post-procedure. All available follow-up data informing on short and long-term safety and efficacy of the Symplicity renal denervation system will be presented.
TEN-YEAR LEGACY EFFECTS OF DELAYED LIPID LOWERING DRUG TREATMENT ON CARDIOVASCULAR DISEASE IN THE SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP2)
Ho CLB a , Chowdhury EK b , Breslin M a , Doust J c , Reid CM b,d Background: Lipid lowering drug treatment (LLT) provides benefits for the primary prevention of cardiovascular disease (CVD) in high risk populations. The benefits may vary considerably depending on the initial levels of CVD risk, irrespective of initial lipid levels. There is evidence supporting the benefits of LLT for sufficiently high CVD risk populations, but limited evidence for lower risk populations, and mixed evidence for the elderly. Aims: To investigate the effects of LLT in the elderly who had baseline LLT (early treatment) and those who did not (delayed treatment) on all-cause and CVD mortality in a randomized trial of BP-lowering therapy.
Methods:
We conducted a post-hoc survival analysis of participants in the Second Australian National Blood Pressure study (ANBP2). ANBP2 was a randomized, open-label study with blinded end point assessment in participants aged 65 to 84 years. We re-stratified the participants into two groups: those who were undergoing LLT at trial entry and those who were not, regardless of randomization status within the trial. We also excluded participants who had a previous history of CVD and those who initiated LLT during the trial period. We calculated 4-year in-trial fatal and non-fatal outcomes, and extended 6-year post-trial fatal outcomes. Thus a 10-year legacy effect of delayed LLT could be tested. Results: The analysis included 4257 participants (LLT group: 648, non-LLT group: 3609) aged 72.0 ± 5.0 years who at baseline had an average 5-year CVD risk (18.3 ± 7.5%) with a total cholesterol level of 5.5 ± 0.9 mmol/l. In the overall study population, we found a significant reduction in all-cause mortality (HR 0.65, 95% CI 0.43-0.98; P = 0.04) for the group treated with LLT, but also a statistically significant increase in new onset diabetes observed (HR 1.51, 95% CI 1.05-2.16; P = 0.03) during the in-trial period. Over a 10-year follow-up period (including post-trial), the effects became significant for cancer death with a HR of 0.55 (95%CI 0.39-0.78; P = 0.001) and all-cause mortality remained significant with a HR of P=0.003) . No significant effects were found for CVD mortality. All analyses were adjusted for baseline characteristics. Conclusion: Our study showed legacy effects of delayed LLT regarding deaths from any causes and cancer. Thus, our finding contributes evidence to recommend the earlier treatment of LLT in high CVD risk older individuals (age > 65 years).
Background: Markers of vascular function and incidence of cardiovascular events have been shown to be more strongly associated with central aortic pressure (cAP) compared to peripheral arterial pressure (pAP). However, the potential clinical use of hemodynamic indices of cAP and pAP as markers of target organ damage (TOD) has not been well established. Aims: To assess the association of cAP and pAP with markers of TOD and to seek any differences related to age. Methods: Conventional indices of cAP and pAP pulse waveforms (pulse pressure [aPP, pPP] , waveshape form factor and augmentation index) were assessed in relation to TOD in 770 hospital inpatients (age 60.0±10.0 years, 473 males) with primary hypertension. TOD was quantified in terms of arterial stiffness as measured by carotid-femoral pulse wave velocity (cfPWV), carotid intima-media thickness (IMT) and urine albumin-to-creatinine ratio (ACR). Subclinical TOD was defined as carotid IMT > 0.9 mm, urine ACR > 3.5 mg/mmol in females and > 2.5 mg/mmol in males and/or cfPWV > 12 m/s. Results: For the whole cohort, cPP and pPP showed a significant positive correlation with cfPWV (r = 0.41 vs. r = 0.40; P < 0.01), ACR (r = 0.24 vs. r = 0.27; P < 0.01) and carotid IMT (r = 0.14 vs. r = 0.15; P < 0.01). Each SD increase in pPP and cPP was associated with respective odds ratios (OR) of 2.7, 2.9 (cfPWV), 1.2, 1.4 (ACR), 1.46, 1.53 (IMT). When corrected for confounding variables, cPP had higher predictive power for TOD for age ≥ 60 years compared to pPP. Conclusion: Both pPP and cP showed an association with TOD in a hypertensive population. However, compared to pPP, cPP provides independent and additional information associated with TOD in elderly hypertensive subjects. Additional hemodynamic indices of cAP as potential biomarkers of subclinical TOD need to be validated by further prospective studies. Background: Primary aldosteronism (PA), a common and potentially curable form of hypertension, is characterized by excessive and autonomous production of aldosterone by the adrenal glands. Aldosterone is the major regulator of sodium and potassium excretion due to its effects on the epithelial sodium channel (ENaC) and sodium chloride cotransporter (NCC) in the renal distal nephron through various mechanisms. Relevant animal studies demonstrate aldosterone stimulates prostasin to activate ENaC by increasing α-subunit (α-ENaC) abundance and inducing γ-subunit (γ-ENaC) cleavage. Urinary exosome extraction techniques enable the study of sodium transporters non-invasively in humans. Aims: To explore urinary exosomal γ-ENaC abundance in hypertensive patients undergoing fludrocortisone (mineralocorticoid) suppression testing (FST) to diagnose or exclude PA, as a means of assessing γ-ENaC cleavage induced by mineralocorticoid administration in humans. Methods: Morning spot urine samples from hypertensive patients (n=13, 6 females/7 males) who underwent FST were collected basally (D0) and after 4 days mineralocorticoid administration (D4), treated with protease inhibitor and were stored at -80 o C. Urinary exosomes were harvested by progressive ultracentrifugation, followed by immunoblotting to measure abundance of prostasin and cleaved forms of γ-ENaC.
CAN EFFECTS OF MINERALOCORTICOIDS ON ENDOTHELIAL
Results: Preliminary data have demonstrated a trend towards an increase in prostasin in response to fludrocortisone administration (fold change = 1.26, P=0.07). However, dominant γ-ENaC cleavage products (55 kDa) remained unchanged. Conclusion: Prostasin and γ-ENaC cleavage are detectable in human urinary exosomes in PA and healthy subjects. A trend towards an increase in prostasin during 4-day mineralocorticoid administration was observed. Dominant γ-ENaC cleavage products (55 kDa) represent cleavage by prostasin/kallikrein, and remained unchanged (fold change = 1.05) in response to mineralocorticoid administration, which suggests that mineralocorticoid-induced increases in prostasin may not alter the abundance of prostastin/kallikrein γ-ENaC cleavage products in urinary exosomes. Background: Because the aldosterone/renin ratio (ARR) can be falsely elevated (false-positive) during case detection for primary aldosteronism (PA), confirmatory testing such as by the fludrocortisone suppression test (FST) is necessary to definitively confirm or exclude the diagnosis. Fludrocortisone, a synthetic steroid, possesses very potent mineralocorticoid properties along with comparatively very weak glucocorticoid activity. The basis of FST involves the demonstration of ongoing (non-suppressible) aldosterone production in the face of suppression of its main regulator, the renin-angiotensin system (RAS). Angiotensin II can now be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and aldosterone/angiotensin II ratio (AA2R) can be calculated. Aims: To validate a novel angiotensin II assay by evaluating the effects of FST on aldosterone, renin, and angiotensin II among PA and non-PA patients. Methods: We administered 48 PA patients and 20 non-PA patients with 0.1 mg oral fludrocortisone Q6h for 4 days. Blood samples were collected at 7 AM following overnight recumbency and again at 10 AM in an upright position basally (day 0) and on day 4 of FST. PA was confirmed (FST-positive) if upright (at 10 AM) aldosterone was > 130 pmol/L on day 4 of FST, provided upright renin was < 8.4 mU/L, upright cortisol level was lower than recumbent (at 7 AM), and K + was in the normal range. Serum aldosterone concentration (Aldo) was measured by LC-MS/MS. Direct renin concentration (DRC) was determined by chemiluminescent immunoassay. Serum equilibrium angiotensin II (eqAngII) was measured using a novel RAS equilibrium analysis based on LC-MS/MS. Results: Compared to day 0, both the PA and non-PA groups showed significant (P <0.01) decreases in Aldo, DRC, and eqAngII on day 4 of FST, but the decrease of Aldo at 7 AM in the non-PA group was not statistically significant (P >0.05). Although Aldo at 10 AM in PA patients fell from 423 (263-588) to 315 (192-476) pmol/L, values were still higher than 130 pmol/L in all patients (but in none of the non-PA patients), meeting the diagnostic criterion of confirming PA. On day 4 of FST, PA patients continued to show significantly (P <0.01) higher levels of Aldo, the ARR and the AA2R than non-PA patients, but the differences in DRC and eqAngII between the two groups were no longer significant (P >0.05) as both were suppressed to extremely low levels by fludrocortisone administration. DRC and eqAngII at 10 AM on day 4 of FST also showed significant (P <0.01) positive correlations in the two groups with Spearman correlation coefficients of 0.746 and 0.551, respectively. Conclusion: The changes of renin and eqAngII, the ARR and AA2R all showed good consistency during FST, indicating that this novel angiotensin II assay may have the potential for future application in distinguishing PA and non-PA. Background: Primary aldosteronism (PA), also known as Conn's syndrome, is the most common specifically treatable and potentially curable cause of hypertension. It has a prevalence of 4.6-13% in patients with hypertension and up to 20% in patients with resistant hypertension, based primarily on overseas literature. There is limited data regarding the epidemiology and diagnosis of PA in Australia. Aims: To analyse the referral pattern and disease characteristics of hypertensive patients referred to the Endocrine Hypertension Service at Monash Health. Methods: We conducted a retrospective review of 99 patients who attended the Endocrine Hypertension Service since its establishment in May 2016. Each patient completed a questionnaire that covered socio-demographics, diet and exercise, diagnosis of hypertension, medications and comorbidities. Sources of referral, comorbidities, clinical outcomes, and biochemical outcomes were obtained from Scanned Medical Records and Monash Pathology database. Results: Only 3% of referrals were made at the first presentation of hypertension, whilst 97% were made for complex hypertension and/or end organ damage. The majority of referrals (67%) was derived from tertiary centres while only 20% came from primary care centres. The diagnosis of PA was delayed, with the majority of patients having had hypertension for at least 6 years prior to their referral. On presentation, 32% of patients had chronic renal failure, left ventricular hypertrophy, stroke or atrial fibrillation. Of the patients diagnosed with PA, targeted management of aldosterone-producing adenoma (APA) by adrenalectomy resulted in complete resolution of hypertension in 75% and biochemical cure in 100%. Targeted management of bilateral adrenal hyperplasia or APA (where patient factors led to preferred medical management over adrenalectomy) also led to significant improvement in blood pressure control. All patients who underwent adrenalectomy and 73% of patients who received medical management required a decreased number of anti-hypertensive medications.
APPLICATION OF A NOVEL ANGIOTENSIN II ASSAY IN CONFIRMATORY TESTING FOR PRIMARY ALDOSTERONISM

CURRENT PATTERN OF PRIMARY ALDOSTERONISM DIAGNOSIS: DELAYED AND COMPLICATED
Conclusion:
The diagnosis of PA remains delayed and complicated. The majority of patients are referred by tertiary institutions after enduring longstanding hypertension that is already complicated by end-organ damage. Given that appropriate management of PA resulted in significant clinical and biochemical improvement, we need to increase awareness of PA in primary care so that the diagnosis can be made early for maximal health benefits. Background: Primary aldosteronism (PA), a common and potentially curable form of hypertension is characterized by excessive and autonomous production of aldosterone by the adrenal glands. Aldosterone serves as a signal to increase the expression and activity of sodium chloride cotransporter (NCC) and the epithelial sodium channel (ENaC) in response to a low sodium diet. Potassium is now also thought to be a major regulator of NCC. Acute sodium loading results in a rapid decrease of aldosterone in humans, and a concomitant inhibition of ENaC has been observed in murine studies. Aims: To explore urinary exosomal NCC abundance and phosphorylation in hypertensive patients undergoing saline suppression testing (SST) to diagnose or exclude PA, as a means of non-invasively assessing variations of NCC abundance and its phosphorylation. Methods: Urine samples collected from hypertensive patients who underwent SST (seated posture n=5 (3 female and 2 male), recumbent posture n=4 (1 female and 3 male)) were collected before and after 4-hour acute sodium loading. Samples were treated with protease inhibitor and stored at -80 o C. Urinary exosomes were harvested by progressive ultracentrifugation, followed by immunoblotting to measure abundance of NCC and its phosphorylated form (pNCC). Results: Preliminary data demonstrated a trend toward decrease in abundance of NCC (mean foldchange = 0.48) and a significant decrease in abundance of pNCC (mean fold-change = 0.48; P =0.029) in response to 4-hour sodium loading in both seated and recumbent postures. The reduction in abundance of pNCC appeared to be greater in the seated posture (mean fold change = 0.34) compared to the recumbent posture (0.94). During 4-hour sodium loading, plasma potassium concentration was 3.95 mmol/L pre infusion and 3.94 mmol/L post infusion (P=0.91), and plasma aldosterone was 256 pmol/L pre infusion and 121 pmol/L post infusion (P =0.001) in both postures. Conclusion: Changes in NCC abundance and its phosphorylation in response to acute sodium loading are detectable in human urinary exosomes in PA. The observable decrease in NCC abundance and significant decrease in pNCC abundance suggests acute sodium loading may at least partially induce sodium excretion by reducing NCC abundance and its phosphorylation, independent of plasma potassium. The apparent differences in findings between seated and recumbent postures requires further investigation.
ACUTE SODIUM LOADING DECREASES ABUNDANCE OF SODIUM CHLORIDE TRANSPORTER AND ITS PHOSPHORYLATION IN HUMAN URINARY EXOSOMES
Background:
The carotid body (CB) is considered a therapeutic target in diseases mediated by the sympathetic nervous system. Aims: To assess the safety and effectiveness of a catheter-based system to ablate the carotid body and reduce blood pressure (BP) in patients with resistant hypertension. Methods: This single-arm multicenter prospective study was approved for treatment of 45 patients. Inclusion criteria included stability on three or more antihypertensive medications and daytime systolic ambulatory BP ≥ 135 mmHg. The primary safety endpoint was the rate of death, hospitalization for hypertensive crisis, and device-or procedure-related serious adverse event (SAE) at 1 month. The secondary safety endpoint was the rate of death and hospitalization for hypertensive crisis at 6, 12, 18 and 24 months. Effectiveness was defined as the change in 24-h systolic ambulatory BP between baseline and 1, 3, 6 and 12 months. The procedure was performed using a proprietary ablation catheter delivering ultrasound energy via the jugular vein with intravascular imaging guidance. Results: To date, long-term follow up has been obtained in 22 patients. The study population consisted of patients with a mean age of 63 years, 69% male, mean BMI of 30±4 kg/m 2 , and diabetes in 22%. Mean baseline 24-h ABPM was 154±13/94±12 mmHg. Two instances of post-procedural chest pain have been reported to date that were resolved by the one-month follow up. One serious adverse event was reported related to groin access complications. One TIA was reported several hours after the procedure, likely related to procedural hypertension. The 24-h ABPM was reduced by an average of 9±11/5±7 mmHg at 1 month, 8±16/5±10 mmHg at 3 months, and 11±13/7±8 mmHg at 6 months. Conclusion: Transvenous catheter-based ablation of the carotid body seems to be a promising approach, with results that persist over time. The results need to be confirmed in larger, randomized evaluations. Background: Renal dysfunction occurring secondary to heart failure (HF) involves a complex interplay of mechanisms, among which renal fibrosis is a key culprit. It has been shown that levels of glutathione, the body's predominant antioxidant, when augmented contributes to fibrosis development in cardiac and renal dysfunction. Aims: To determine if restoring glutathione capacity can reverse renal fibrosis and improve renal function in mice with HF. Methods: Eighteen-week old mice with dilated cardiomyopathy (DCM; n=16) and age-matched littermate controls (WT; n=18) were used. All mice received treatment with either N-acetylcysteine (NAC; 40 mg/kg/day), a precursor for glutathione, or saline for a period of 8 weeks via subcutaneously implanted minipumps. At study end, cardiac and renal structure, function, and fibrosis, renal gene expression, and renal glutathione content were assessed in all mice. In a separate cohort, these data were collected in 18-week-old mice (WT; n=16; DCM; n=17) for the evaluation of baseline parameters. Results: At baseline, mean LV wall thickness and ejection fraction were 23% and 36% lower, respectively, in DCM mice than WT (P <0.001). This was accompanied by 88%, 73% and 40% greater levels of tubulointerstitial fibrosis, glomerular fibrosis, and renal oxidized glutathione content, respectively, in DCM mice compared to WT (P ≤0.05). After 8 weeks of treatment, renal oxidized glutathione content was 52% less in NAC-treated DCM mice than untreated DCM mice (P <0.01). This was associated with 99% and 70% less tubulointerstitial and glomerular fibrosis, respectively, in NACtreated DCM mice compared to untreated DCM mice (P <0.001). Of note, tubulointerstitial and glomerular fibrosis were lower in NAC-treated DCM mice compared to levels at baseline (P <0.05). Lastly, glomerular filtration rate (GFR) was 38% greater in NAC-treated DCM mice compared to untreated DCM mice (P <0.01). Importantly GFR in NAC-treated DCM mice was comparable to that of age-matched WT mice (P=0.99). Treatment with NAC, however, had no effect on cardiac structure or function in DCM mice (P ≥0.20). Conclusion: NAC therapy reversed renal fibrosis and improved renal function in mice with DCM, potentially by restoring the reduced renal glutathione content. Background: Brachial blood pressure (BP) is the reference standard for hypertension management, but central systolic BP may significantly differ from brachial systolic BP. The extent to which clinical diagnosis and management may diverge on the basis of brachial versus central BP is uncertain at the population level. Aims: To determine differences in the diagnosis of hypertension in the community, based on brachial and central BP values. Methods: Brachial and central BP (average of 3 recordings) were measured using cuff oscillometry (SphygmoCor ® -XCEL) among 890 adults participating in a community-screening program. Brachial BP status was determined according to guideline thresholds (i.e., ≥140/90 mmHg) and central BP status according to published limits (i.e., ≥130/90 mmHg). Theoretical differences in clinical diagnosis were derived from threshold differences between brachial BP and central BP. Results: Participants were aged 47±18 (mean±SD) years (53% women). Prevalence of hypertension according to brachial BP was 35.5% (n=316), but only 75% (n=237) of these people also had central hypertension, leaving another 25% (n=79) 129±4 mmHg for non-diabetic vs. diabetic BPH, n=5 and 6, respectively). Diabetic BPN and BPH mice showed significantly greater albuminuria than non-diabetic controls, with diabetic BPN showing less albuminuria than diabetic BPH (439±73 vs. 1205±196 μg/24 h, n=8, 7). Plasma cystatin C was significantly lower in diabetic animals, with no difference between strains. HPLC measurement of cortical noradrenaline showed significantly greater levels in kidneys from hypertensive mice, but, interestingly, diabetic mice had significantly less renal noradrenaline. Renal cortical peroxide formation was increased in non-diabetic BPH mice and while activity of the anti-oxidant enzyme catalase was increased in non-diabetic BPH mice it was significantly less in diabetic BPH animals (non-diabetic vs. diabetic BPH 104±8 vs. 63±6 nmol/min/ml, n=8/group).
N-ACETYLCYSTEINE REVERSES ESTABLISHED RENAL FIBROSIS AND RESTORES RENAL FUNCTION IN A MOUSE MODEL OF DILATED CARDIOMYOPATHY
CLINICAL DECISIONS ON HYPERTENSION MANAGEMENT WILL DIFFER ON THE BASIS OF BRACHIAL VERSUS CENTRAL BLOOD PRESSURE
Conclusion:
Kidneys of non-diabetic hypertensive mice show greater renal oxidative stress than normotensive mice. While diabetic hypertensive animals have greater oxidative stress, they had lower catalase activity, indicating compromised ability to deal with hypertension leads to increases in oxidative stress. This could contribute to greater renal neuropathy, further compromising renal function. This mechanism may underlie the poor outcome for patients with hypertensive diabetic nephropathy.
